Colin Bristow
Stock Analyst at UBS
(1.14)
# 3,462
Out of 4,826 analysts
95
Total ratings
32.73%
Success rate
-14.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $15.23 | +11.62% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $279.80 | +14.01% | 8 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.05 | +280.95% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.68 | +90.22% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $23.88 | +17.25% | 13 | Feb 5, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $4 → $2.2 | $0.53 | +315.17% | 5 | Jan 27, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $82.84 | +44.86% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $40.78 | +74.10% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $102.81 | -6.62% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $500.19 | +17.16% | 13 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $121.80 | +65.85% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.69 | +846.75% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $603.58 | +82.08% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $7.84 | +589.22% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $63.66 | +162.33% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $821.46 | -48.87% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $6.81 | -70.63% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.76 | +2,257.26% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $196.07 | -25.54% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $50.06 | +49.82% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.62 | +1,504.94% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.02 | +79.28% | 1 | Aug 23, 2021 |
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $15.23
Upside: +11.62%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $279.80
Upside: +14.01%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.05
Upside: +280.95%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.68
Upside: +90.22%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $23.88
Upside: +17.25%
ALX Oncology Holdings
Jan 27, 2025
Maintains: Buy
Price Target: $4 → $2.2
Current: $0.53
Upside: +315.17%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $82.84
Upside: +44.86%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $40.78
Upside: +74.10%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $102.81
Upside: -6.62%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $500.19
Upside: +17.16%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $121.80
Upside: +65.85%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.69
Upside: +846.75%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $603.58
Upside: +82.08%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $7.84
Upside: +589.22%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $63.66
Upside: +162.33%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $821.46
Upside: -48.87%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $6.81
Upside: -70.63%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $0.76
Upside: +2,257.26%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $196.07
Upside: -25.54%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $50.06
Upside: +49.82%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.62
Upside: +1,504.94%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.02
Upside: +79.28%